Atorvastatin

• Description :

  Atorvastatin is an orally active HMG-CoA reductase inhibitor, has the ability to effectively decrease blood lipids. Atorvastatin inhibits human SV-SMC proliferation and invasion with IC50s of 0.39 μM and 2.39 μM, respectively[1][2][3].

• UNSPSC :

  12352005

• Hazard Statement :

  H302, H315, H319, H335

• Target :

  Autophagy; HMG-CoA Reductase (HMGCR)

• Type :

  Reference compound

• Related Pathways :

  Autophagy; Metabolic Enzyme/Protease

• Applications :

  Metabolism-sugar/lipid metabolism

• Field of Research :

  Metabolic Disease; Inflammation/Immunology; Cancer

• Assay Protocol :

  https://www.medchemexpress.com/atorvastatin.html

• Concentration :

  10mM

• Purity :

  99.64

• Solubility :

  DMSO : ≥ 100 mg/mL

• Smiles :

  O=C(C(C(C1=CC=CC=C1)=C(C2=CC=C(F)C=C2)N3CC[C@@H](O)C[C@@H](O)CC(O)=O)=C3C(C)C)NC4=CC=CC=C4

• Molecular Formula :

  C33H35FN2O5

• Molecular Weight :

  558.64

• Precautions :

  H302, H315, H319, H335

• References & Citations :

  [1]Nawrocki, J.W., et al., Reduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor. Arterioscler Thromb Vasc Biol, 1995. 15 (5) : p. 678-82.|[2]Santodomingo-Garzón T, et al. Atorvastatin inhibits inflammatory hypernociception. Br J Pharmacol. 2006 Sep;149 (1) :14-22.|[3]Turner NA, et al. Comparison of the efficacies of five different statins on inhibition of human saphenous vein smooth muscle cell proliferation and invasion. J Cardiovasc Pharmacol. 2007 Oct;50 (4) :458-61.|[4]Song XJ, et al. Atorvastatin inhibits myocardial cell apoptosis in a rat model with post-myocardial infarction heart failure by downregulating ER stress response. Int J Med Sci. 2011;8 (7) :564-72.|[5] Li Y, et al. Inhibition of endoplasmic reticulum stress signaling pathway: A new mechanism of statins to suppress the development of abdominal aortic aneurysm. PLoS One. 2017 Apr 3;12 (4) :e0174821.|[6]Ming-Bai Hu, et al. Atorvastatin induces autophagy in MDA-MB-231 breast cancer cells. Ultrastruct Pathol. Sep-Oct 2018;42 (5) :409-415.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  Launched

• Citation 01 :

  Acta Diabetol. 2025 Mar 27.|Acta Pharmacol Sin. 2024 Jun;45 (6) :1316-1320.|Arterioscler Thromb Vasc Biol. 2022 May;42 (5) :644-658.|Biomed Pharmacother. 2023 Oct:166:115323.|Biotechnol Bioeng. 2021 Dec;118 (12) :4687-4698.|Cancer Lett. 2023 Jan 1:552:215976.|Cell Cycle. 2019 Dec;18 (23) :3337-3350.|Cell Cycle. 2021 Oct;20 (20) :2160-2173.|Chem Biol Interact. 2025 Oct 22:420:111671.|Clin Pharmacol Ther. 2025 Jul 14.|Emerg Microbes Infect. 2025 Dec;14 (1) :2470371.|Endocrinology. 2022 Jul 1;163 (7) :bqac076.|Environ Sci Technol Lett. 2025 Apr 8.|Eur J Pharmacol. 2023 Oct 5:956:175938.|Eur J Pharmacol. 2024 Feb 5:964:176261.|Eur J Pharmacol. 2025 Feb 5:177357.|Exp Cell Res. 2023 Dec 15;433 (2) :113829.|Exp Neurol. 2025 May 16:115305.|FEBS Open Bio. 2025 Aug 8.|Front Cell Dev Biol. 2022 Mar 3;10:806081.|Front Pharmacol. 2025 Apr 30:16:1573032.|Inflammation. 2024 Oct 31.|Int Immunopharmacol. 2025 Dec 3:166:115644.|Int J Mol Sci. 2023 Apr 19;24 (8) :7492.|J Appl Toxicol. 2024 Apr 19|J Appl Toxicol. 2024 Aug;44 (8) :1198-1213.|J Mol Neurosci. 2022 Mar;72 (3) :565-573.|J Nat Prod. 2022 Jul 22;85 (7) :1738-1750.|J Neuroimmunol. 2020 Oct 24:350:577429.|J Tradit Complement Med. 2024 Mar 29.|Life Sci. 2025 Jun 1:370:123571.|Med Gas Res. 2025 Mar 1;15 (1) :148-155.|MedComm (2020) . 2024 Aug 31;5 (9) :e681.|Mol Cell. 2021 Jul 1;81 (13) :2736-2751.e8.|Nat Aging. 2025 Aug 26.|Naunyn Schmiedebergs Arch Pharmacol. 2023 Dec;396 (12) :3659-3670.|Oncogene. 2022 Dec;41 (49) :5266-5278.|Oncologie. 2025 May 26.|Orebro University. 2024.|Phytomedicine. 2023 Jul 26;119:154997.|Phytomedicine. 2025 Jul:142:156713.|Phytomedicine. 2025 Oct:146:157128.|Proteomics. 2023 Aug;23 (16) :e2300041.|Research Square Preprint. 2021 Dec.|Research Square Preprint. 2022 Jun.|Research Square Preprint. 2024 Apr 9.|Sci Rep. 2020 Jan 28;10 (1) :1308.|Signal Transduct Target Ther. 2023 Dec 25;8 (1) :457.|Signal Transduct Target Ther. 2025 Nov 12;10 (1) :366.|SSRN. 2025 Apr 9.|Adv Sci (Weinh) . 2024 Jul 5:e2403451.|Arch Biochem Biophys. 2025 Jan 21:765:110316.|bioRxiv. 2024 Jul 3:2024.07.01.601474.|Cell Death Dis. 2021 May 13;12 (5) :482.|Endocrinology. 2018 May 1;159 (5) :2008-2021.|Free Radic Biol Med. 2024 Aug 1:220:179-191.|Front Bioeng Biotechnol. 2022 Mar 17;10:826093.|Nat Metab. 2025 Sep 22.|Pharmaceutics. 2022 Jan 12;14 (1) :176.|Eur J Med Chem. 2024 Dec 5:279:116842.

• CAS Number :

  [134523-00-5]